2 results match your criteria: "France. jeanmaurice.delabar@icm-institute.org.[Affiliation]"
Increased plasma DYRK1A with aging may protect against neurodegenerative diseases.
Transl Psychiatry
April 2023
Paris Brain Institute (ICM), Centre National de la Recherche Scientifique (CNRS) UMR 7225, INSERM U1127, Sorbonne Université, Hôpital de la Pitié-Salpêtrière, Paris, 75013, France.
Early markers are needed for more effective prevention of Alzheimer's disease. We previously showed that individuals with Alzheimer's disease have decreased plasma DYRK1A levels compared to controls. We assessed DYRK1A in the plasma of cognitively healthy elderly volunteers, individuals with either Alzheimer's disease (AD), tauopathies or Down syndrome (DS), and in lymphoblastoids from individuals with DS.
View Article and Find Full Text PDFPrenatal treatment with EGCG enriched green tea extract rescues GAD67 related developmental and cognitive defects in Down syndrome mouse models.
Sci Rep
March 2019
Université Paris-Diderot, Sorbonne Paris Cité, Adaptive Functional Biology, National Centre for Scientific Research (CNRS), UMR 8251, Paris, France.
Article Synopsis
- Down syndrome is caused by having an extra chromosome 21, leading to developmental challenges, and researchers are exploring prenatal treatments to improve brain function in affected fetuses.
- The study investigated the use of green tea extract, rich in EGCG, to inhibit the DYRK1A protein during pregnancy in mouse models, showing positive effects on neuron balance and density.
- Results indicated that prenatal EGCG treatment improved cognitive abilities in certain memory tests for Dp(16)1Yey mice, suggesting a potential intervention strategy for Down syndrome.